LabCompass

Publications

294

Citations

11,985

Est. group size

Recurring co-author estimate

Active years

48

Publishing since 1979

Research summary
AI-generated

Kenneth Cornetta studies gene therapy, focusing on using engineered viruses (such as lentiviral and AAV vectors) to deliver corrective genes into blood-forming stem cells to treat inherited diseases like sickle cell disease and immune deficiencies. A major part of the work involves developing methods to test the safety of these therapies, for example by tracking where the delivered genes insert into the genome and checking for contaminating viruses. The research also addresses making gene therapies accessible in low- and middle-income countries and related global health efforts.

Viral vector gene therapyHematopoietic stem cell transplantationGene therapy safety and vector integrationCell and immune therapies (CAR-T / T-cell receptor)Global access to gene therapy

Publication activity has been fairly steady, averaging around nine papers per year over the past five years, with a notable spike in 2023.

Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026

Publication cadence
Publications per year over the last 10 years — averaging 9.2/year recently
2017: 5 publications172018: 4 publications182019: 7 publications192020: 8 publications202021: 9 publications212022: 5 publications222023: 28 publications28232024: 6 publications242025: 5 publications252026: 2 publications26
Recent publications
Publishes in
  • Molecular Therapy×7
  • Blood×4
  • Human Gene Therapy×3
  • Journal of Pain and Symptom Management×3
  • New England Journal of Medicine×2

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 11, 2026.

Claim or correct this profile